{"id":54572,"date":"2024-01-19T10:48:04","date_gmt":"2024-01-19T10:48:04","guid":{"rendered":"https:\/\/www.touchcardio.com\/?p=54572"},"modified":"2024-01-22T09:35:33","modified_gmt":"2024-01-22T09:35:33","slug":"transcatheter-tricuspid-valve-intervention-for-the-treatment-of-tricuspid-regurgitation-with-triclip-all-you-need-to-know","status":"publish","type":"post","link":"https:\/\/www.touchcardio.com\/interventional-cardiology\/journal-articles\/transcatheter-tricuspid-valve-intervention-for-the-treatment-of-tricuspid-regurgitation-with-triclip-all-you-need-to-know\/","title":{"rendered":"Transcatheter Tricuspid Valve Intervention for the Treatment of Tricuspid Regurgitation with TriClip: All You Need to Know"},"content":{"rendered":"

Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1<\/sup><\/span>\u00a0If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along with increased morbidity and mortality. This disease is highly undertreated due to high complication rates and in-hospital mortality reaching up to 10% with surgical treatment, which until a few years ago was the only corrective therapy available.2<\/sup><\/span>\u00a0A novel and revolutionary approach has been developed for the treatment of TR in the form of transcatheter tricuspid valve intervention (TTVI) with different techniques. In this article, we aim to discuss in detail the edge-to-edge technique for the repair of significant TR with the TriClip device (Abbott, Santa Clara, CA, USA).<\/p>\n

Aetiologies of tricuspid regurgitation<\/h1>\n

Depending on the aetiology, TR is further classified as primary or secondary.3<\/sup><\/span>\u00a0Primary TR occurs as a result of isolated valvular apparatus anomalies, which may be congenital or acquired. Whereas secondary TR, also known as functional regurgitation, is caused by extrinsic events affecting the tricuspid valve (TV) and represents the vast majority of the cases. The different aetiologies are summarized in\u00a0Table 1<\/em><\/span>.3<\/sup><\/span><\/p>\n

\n

Table 1: <\/span>Causes of tricuspid regurgitation<\/h2>\n
\n\n\n\n\n\n
\n

Primary tricuspid regurgitation<\/p>\n<\/td>\n

\n

Secondary tricuspid regurgitation<\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

\n

1. Congenital:<\/p>\n

    \n
  • \n

    Ebstein\u2019s anomaly<\/p>\n<\/li>\n

  • \n

    Dysplasia or hypoplasia of tricuspid valve<\/p>\n<\/li>\n

  • \n

    Double orifice tricuspid valve<\/p>\n<\/li>\n

  • \n

    Tricuspid valve tethering with perimembranous ventricular septal aneurysm or defect<\/p>\n<\/li>\n

  • \n

    Connective tissue disorder (e.g. Ehlers-Danlos syndrome, Marfan syndrome)<\/p>\n<\/li>\n<\/ul>\n

    2. Acquired:<\/p>\n

      \n
    • \n

      Chest wall trauma<\/p>\n<\/li>\n

    • \n

      Direct valve trauma secondary to right ventricular intramyocardial biopsy, pacemaker\/ICD insertion or removal<\/p>\n<\/li>\n

    • \n

      Drug-induced: anorectic drugs\/ appetite suppressants, pergolide, fenfluramine, and phentermine<\/p>\n<\/li>\n

    • \n

      Carcinoid syndrome: fixation of leaflets in semi- open position due to thickening and retraction of fibrous leaflets and subvalvular apparatus<\/p>\n<\/li>\n

    • \n

      Rheumatic valve disease<\/p>\n<\/li>\n

    • \n

      Infective endocarditis<\/p>\n<\/li>\n

    • \n

      Marantic endocarditis: SLE\/RA<\/p>\n<\/li>\n

    • \n

      Tricuspid valve prolapse\/ flail associated with myxomatous degeneration (Barlow\u2019s disease)<\/p>\n<\/li>\n<\/ul>\n<\/td>\n

\n